Oniangue-Ndza C, Kamgar F, Schneider RP, Teitsson S, Knight C. Cost-effectiveness of nivolumab as an adjuvant treatment of muscle-invasive urothelial carcinoma at high risk of recurrence in Switzerland. Poster presented at the ISPOR Europe 2022; November 6, 2022. Vienna, Austria. [abstract] Value Health. 2022 Dec 1; 25(12):S146. doi: 10.1016/j.jval.2022.09.708

OBJECTIVES: To assess the cost-effectiveness of nivolumab versus surveillance  in Switzerland for the adjuvant treatment of patients with muscle-invasive urothelial carcinoma (UC) at high risk of recurrence who have undergone radical resection

METHODS: A three-state Markov model (disease-free, recurrent, death) was built and run for a lifetime from a healthcare payer perspective. Outcomes of interest were life-years (LYs), quality-adjusted LYs (QALYs), and incremental cost-utility ratios (ICURs). Patient characteristics, efficacy (disease-free survival), safety (adverse event frequencies), and EQ-5D-5L health state utilities (mapped using the EQ-5D-3L from France in alignment with Matter-Walstra et al. (2014) guidance) were derived from the CheckMate 274 study. Outcomes associated with recurrent disease were modelled using survival data from metastatic UC literature. An annual discount rate of 3.0% was applied to costs and health outcomes. The base-case analysis focused on patients with tumor cell PD-L1 expression ≥1% where a scenario analysis based on PD-L1 expression < 1% was explored to assess the impact of PD-L1 expression on ICURs. Deterministic, probabilistic sensitivity analyses, and scenario analysis tested the stability of the results.

RESULTS: Nivolumab led to increased total LYs and QALYs and to higher costs (8.73, 7.02, and CHF 127,005, respectively) versus surveillance (5.77, 4.59, and CHF 75,661, respectively, resulting in an ICUR of CHF 21,158/QALY gained. All tested scenarios and varied inputs in the deterministic sensitivity analyses resulted in < 10% and < 32% change from the base-case ICUR, respectively. Probabilistic sensitivity analyses resulted in an average ICUR of CHF 22,334/QALY gained, with nivolumab having almost 100% probability of being cost-effective at a hypothetical willingness-to-pay threshold of CHF 100,000/QALY gained. For the subgroup with PD-L1 expression <1%, ICUR was CHF 54,990/QALY gained.

CONCLUSIONS: Nivolumab is estimated to be life-extending and cost-effective adjuvant treatment for muscle-invasive regardless of PD-L1 expression in Switzerland.

Share on: